Who gets Prostate cancer?

Winj ane wachni.

Ng'ano ma bedo gi tuwo mar kansa mar prostate?

Tuwo mar kansa mar prostate en tuwo makelo hinyruok ahinya ne chwo, kendo hinyruokno medore kaka ng'ato medo bedo moti.

Kinde mang'eny, ji mang'eny ma hikgi ng'eny moloyo 65 yudo tuwono.

Moko kuom gik manyalo miyo ng'ato obed gi kansa mar prostate gin kaka:

1. Higni: Bedo gi tuwo mar kansa mar prostate medore kaka ng'ato medo bedo moti, kendo thoth joma yudo tuwono gin chwo ma hikgi osekalo 65.

2. Sigand Joot: Chwo ma nigi tuwo mar kansa mar prostate e joodgi, to moloyo wuoro kata owadgi ma nigi tuwo mar kansa mar prostate, gin gi hinyruok maduong' mar bedo gi tuwo mar kansa mar prostate.

3. Timbe mag anyuola: Chwo ma Jo - Amerka ma Jo - Afrika nigi hinyruok maduong ' mar bedo gi kansa mar prostate, kendo gin gi nyalo mar yudo tuwono ka pod gitindo, kendo gin gi tuoche mag ayaki.

4. Lokruok mar anyuola: Lokruok moko mag anyuola, kaka ma yudore e BRCA1 kod BRCA2, nyalo miyo ng'ato obed gi tuwo mar kansa mar prostate.

5. Chiemo: Chiemo moting'o ring'o makwar kod chak mang'eny nyalo miyo ng'ato obed gi tuwo mar kansa mar prostate, to chiemo moting'o olembe kod alode nyalo miyo ng'ato obed gi tuwo mar kansa mar prostate.

6. Bedo gi del mapek: Bedo gi del mapek kata bedo gi del mapek nyalo miyo ng'ato obed gi tuwo mar kansa mar prostate, kendo mano nyalo miyo tuwo mar kansa obed marach moloyo.

7. Chal mar ngima: Chal mar ngima moko, kaka madho ndawa kod bedo maonge gi del, nyalo miyo ng'ato obed gi tuwo mar kansa mar prostate.

Dwarore ni wang'e ni kata obedo ni gik ma kamago nyalo miyo ng'ato obed gi tuwo mar kansa mar prostate, ok ni chwo duto ma nigi gik ma kamago biro bedo gi tuwo mar kansa mar prostate, kendo chwo moko ma onge gik ma nyalo miyo ng'ato obed gi tuwo mar kansa mar prostate.

Timo nonro kinde ka kinde kendo wuoyo gi laktar kuom gik ma chando chunyi nyalo konyo e fwenyo kansa mar prostate chon, e kinde ma inyalo thiedhe maber.

Weche mondik e iye

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Shimodaira K, Nakashima J, Nakagami Y, Hirasawa Y, Hashimoto T, Satake N, Gondo T, Namiki K, Ohori M, Ohno Y: Prognostic Value of Platelet Counts in Patients with Metastatic Prostate Cancer Treated with Endocrine Therapy. Urol J. 2020, 17 (1): 42-49.

Advanced prostate cancer gets a new foe. Johns Hopkins Med Lett Health After 50. 2013, 25 (7): 8.

Vera Badillo FE: Metastatic prostate cancer gets into the biomarker era. Can Urol Assoc J. 2022, 16 (10): 333.

Gerard MJ, Frank-Stromborg M: Screening for prostate cancer in asymptomatic men: clinical, legal, and ethical implications. Oncol Nurs Forum. 1998, 25 (9): 1561-9.

McDowell ME, Occhipinti S, Chambers SK: The influence of family history on cognitive heuristics, risk perceptions, and prostate cancer screening behavior. Health Psychol. 2013, 32 (11): 1158-69.

Razzaghi MR, Mazloomfard MM, Malekian S, Razzaghi Z: Association of macrophage inhibitory factor -173 gene polymorphism with biological behavior of prostate cancer. Urol J. 2019, 16 (1): 32-36.

Ng'at ma kwedo weche mag thieth

Websaitni olos mondo okony ji ng'eyo weche mag thieth, to ok mondo okonygi ng'eyo kaka ginyalo tiyo gi yore mag thieth.

Weche mochiw ok onego oti kodgi e fwenyo kata thiedho tuwo moro, kendo jogo madwaro ng'eyo kaka ginyalo thiedho tuwo moro, onego owuo gi laktar molony.

Ng'e ni neural net ma chiwo dwoko mag penjo, ok en makare ahinya sama iwuoyo kuom kwan mag ji, kaka kwan mar joma nigi tuwo moro.

Kinde duto many paro mar laktar kata ng'at machielo molony e weche thieth e wi tuwo moro. Kik iket kiawa kuom paro mar laktar kata duoko chien kwayo mar thieth nikech gimoro ma isomo e websaitni. Kapo ni iparo ni inyalo bedo gi chandruok mar thieth, luong 911 kata dhi e od thieth machiegni mapiyo. Onge tudruok moro amora e kind laktar gi jatuwo ma yudore e websaitni kata e tiyo kode. BioMedLib kata jotichne, kata ng'ato ang'ata ma konyo e websaitni, ok nyal chiwo paro moro amora, kata ma ok ong'ere, e wi weche ma yudore e websaitni kata e tiyo kode.

Ng'eyo ni ng'ato nigi ratiro mar timo gik moko

Digital Millennium Copyright Act mar 1998, 17 U.S.C. § 512 (the DMCA) chiwo yore mag kony ne joma nigi ratiro mag ndiko ma paro ni weche ma yudore e Intanet ketho ratiro ma gin-go kaluwore gi chike mag ndiko mag piny Amerka.

Kapo ni iyie gi adiera ni weche moro amora ma yudore e websait marwa kata e tijewa ketho ratiro ma in-go mar ndiko weche, in (kata ng'at mochung'ne) inyalo oronwa barua ka ikwayo ni ogol weche ma yudore e websaitno, kata mondo ogeng' ng'ato kik yudgi.

Weche ma ng'ato onego owach nyaka oor e yo mondik kokalo kuom e-mail (ne "Contact" e wi adres mar e-mail).

DMCA dwaro ni ng'eyo ma in-go kuom ketho chik mar copyrights oting'o weche maluwogi: (1) ler mar tij copyrights ma ikwano ni oketho; (2) ler mar weche ma ikwano ni oketho chik mar copyrights kod weche moromo mondo okonywa ng'eyo kama wechego nitie; (3) weche mag tudruok kodi, moriwo adresni, namba mar simo kod adres mar email; (4) weche ma in-go manyiso ni in gi yie maber ni weche ma ondik e yo ma ikwedo ok oyie gi jal ma nigi ratiro mar copyrights, kata gi ng'at mochung'ne, kata gi chik moro amora;

(5) weche ma in iwuon iwacho, ma iketo e bwo buch kuong'ruok, ni weche manie kalatasno gin adier, kendo ni in gi teko mar tiyo gi ratiro mag ndiko ma ji wacho ni oketh;

(6) kod signature mar ng'at ma nigi ratiro mar timo gik moko, kata ng'at ma nigi ratiro mar timo gik moko e lo ng'at ma nigi ratiro mar timo gik moko.

Ka ok iketo weche duto monyis malo kae, mano nyalo miyo idonj e kesno bang'e.

Wuo gi ng'at machielo

Ka in gi penjo kata paro moro amora, yie iornwa e-mail.

Who gets prostate cancer?

Prostate cancer is a disease that primarily affects men, with the risk increasing with age.

It is most commonly diagnosed in men over the age of 65.

Some factors that may increase the risk of developing prostate cancer include:

1. Age: The risk of prostate cancer increases with age, with most cases occurring in men over the age of 65.

2. Family history: Men with a family history of prostate cancer, particularly a father or brother with the disease, have a higher risk of developing prostate cancer themselves.

3. Race: African American men have a higher risk of developing prostate cancer and are more likely to be diagnosed at a younger age and with more aggressive forms of the disease.

4. Genetics: Certain inherited genetic mutations, such as those in the BRCA1 and BRCA2 genes, may increase the risk of developing prostate cancer.

5. Diet: A diet high in red meat and high-fat dairy products may increase the risk of prostate cancer, while a diet rich in fruits and vegetables may decrease the risk.

6. Obesity: Being overweight or obese may increase the risk of developing prostate cancer, as well as the likelihood of the cancer being more aggressive.

7. Lifestyle factors: Certain lifestyle factors, such as smoking and lack of physical activity, may increase the risk of developing prostate cancer.

It is important to note that while these factors may increase the risk of developing prostate cancer, not all men with these risk factors will develop the disease, and some men without any known risk factors may still be diagnosed with prostate cancer.

Regular screening and discussing any concerns with a healthcare provider can help to detect prostate cancer early, when it is most treatable.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.